With the closing of a new funding round, Cellphire has entered its next exciting phase and is poised for rapid growth. Stephen H. Willard, a major shareholder, has decided to step away from his role as CEO and the Board in order to bring in a new CEO to take the company through its new phase of expansion and growth. The Board has identified the company's new CEO who will start with the company in the near future. In the interim, Rafael Jorda, who has been with the company since 2015, will be the acting CEO and manage the company with the assistance of the Executive Management Team.
Cellphire is a Maryland-based biotechnology company that develops and commercializes stabilized cellular materials to treat bleeding and blood-related ailments.